An update on semaglutide for CKD in the presence of T2D

Description

In this Product Explainer, Endocrinologist Prof Richard MacIsaac provides an update on the chronic kidney disease (CKD) indication for semaglutide, explains the PBS criteria and how healthcare professionals can initiate this GLP-1 RA.

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Dr Paige Lanyon-Roberts

Dr Paige Lanyon-Roberts

The New Oral Medications for Obesity – A Practical Guide for GPs

Dr Terri-Lynne South

Dr Terri-Lynne South

Oral GLP1s – What GPs Need to Know

Dr Katherine Spira

Dr Katherine Spira

Menstrual Migraine

Prof Danny Green

Prof Danny Green

GLP1s and Muscle Mass – What Does the Evidence Show?

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Prof Richard MacIsaac

expert

Prof Richard MacIsaac

Endocrinologist, Director, St Vincent’s Hospital Melbourne; Professor, University of Melbourne

Date published: 30 March 2026